CollPlant to Host LightSolver Investor Webinar on September 17, 2026

CollPlant highlights its newly acquired photonic computing subsidiary LightSolver in an investor webinar as it diversifies beyond regenerative medicine.

Rhea-AI Summary

CollPlant (CLGN)/b) will host an investor webinar featuring its subsidiary LightSolver on September 17, 2026, at 8:30 a.m. Eastern Time.LightSolver management will introduce the company and its pure photonic computing technology, including its full-stack Laser Processing Unit (LPU) architecture, targeted computational challenges and applications, current validation and collaboration programs, and its roadmap toward commercial deployment. LightSolver became a subsidiary of CollPlant following completion of an acquisition announced on September 3, 2026, which expands CollPlant’s activities into advanced photonic computing alongside its existing regenerative medicine and 3D bioprinting businesses.

Positive

• LightSolver acquisition completed adds an advanced photonic computing business to CollPlant’s portfolio
• Strategic diversification into deep-tech computing alongside regenerative medicine and 3D bioprinting
• Planned commercialization roadmap for LightSolver’s Laser Processing Unit discussed with investors

Negative

• None.

Key Terms

photonic computing, 3d bioprinting, recombinant human collagen

3 terms

photonic computing technical

"a pioneer of pure photonic computing with the world's first Laser Processing Unit"

Photonic computing uses pulses of light instead of moving electrons to carry out calculations and move information, like replacing electrical wiring with tiny beams of light on a computer chip. It matters to investors because light-based chips promise much faster data processing and lower power use for tasks like large-scale AI and data centers, potentially creating new markets and competitive advantages — but the technology is still emerging and carries development and scaling risks.

3d bioprinting medical

"a focus on 3D bioprinting of tissues and organs"

3D bioprinting is a manufacturing technique that uses printer-like equipment to place living cells and supportive materials layer by layer to create tissues or organ-like structures, similar to building a model one thin slice at a time. It matters to investors because successful bioprinted products could create new medical therapies, reduce lab time and costs, and open markets in drug testing and transplant alternatives, while also carrying long development timelines and regulatory risk.

recombinant human collagen medical

"products are based on its recombinant human collagen produced with"

Collagen produced by inserting human collagen genes into cells or microorganisms so they manufacture the same protein sequence found in people; the product is purified from those cultured cells rather than taken from animal tissue. It matters to investors because it is a scalable, standardized source of human-sequence collagen used in medical products (wound care, implants, cosmetics and drug delivery), and its production method affects manufacturing cost, regulatory review, intellectual property and market differentiation—like making a recipe in a factory instead of harvesting it from different farms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REHOVOT, Israel, Sept. 10, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd. (Nasdaq: CLGN) today announced that its subsidiary LightSolver Ltd. ("LightSolver"), a pioneer of pure photonic computing with the world's first Laser Processing Unit™ (LPU™), a fundamentally new computing architecture that uses light itself to compute, will host an investor webinar on Thursday, September 17, 2026, at 8:30 a.m. Eastern Time.

During the webinar, LightSolver management will provide an introduction to the company and its technology, including its full-stack photonic computing architecture, the computational challenges and applications it is designed to address, current validation and collaboration programs, and the company's roadmap toward commercial deployment.

LightSolver became a subsidiary of CollPlant following completion of the acquisition announced on September 3, 2026. This transaction marks a pivotal strategic expansion for CollPlant, diversifying its portfolio into the deep-tech frontier of advanced photonic computing. The integration is expected to provide additional resources to advance LightSolver's technology roadmap, expand strategic partnerships and accelerate its transition toward commercialization.

Webinar Information

Date: Thursday, September 17, 2026
Time: 8:30 a.m. Eastern Time
Registration: https://www.veidan-conferencing.com/collplant

Attendees are invited to submit questions in advance to investors@lightsolver.com by end of day on September 15, 2026.

About CollPlant

CollPlant is a pioneering technology company operating at the forefront of both regenerative medicine and advanced high-performance computing. Following the strategic acquisition of LightSolver, CollPlant has expanded its footprint into the deep-tech sector, integrating a proprietary all-optical computing architecture known as the Laser Processing Unit (LPU). This bold diversification positions the Company to address some of the world's most computationally intensive workloads across aerospace, defense, and Physical AI, while continuing to drive its core biotech innovations.

In the healthcare sector, CollPlant is ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair, and medical aesthetics. The Company's products are based on its recombinant human collagen produced with CollPlant's proprietary plant-based genetic engineering technology, addressing indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing.

For more information about CollPlant, visit www.CollPlant.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the anticipated benefits, and growth opportunities arising from the acquisition of LightSolver by CollPlant; the future development, commercialization and market adoption of LightSolver's Laser Processing Unit (LPU) technology; and the future prospects, business plans and growth strategies of CollPlant, LightSolver and the combined business. Forward-looking statements can be identified by words such as "anticipate," "believe," "expect," "intend," "plan," "may," "should," "could," "might," "seek," "target," "will," "project," "continue" and similar expressions or the negative of such terms. These forward-looking statements are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of our control. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the risk that the anticipated benefits of the transaction are not realized, or are not realized within the expected timeframe; risks associated with integrating LightSolver's business, operations and personnel; LightSolver's ability to achieve anticipated technological and commercial milestones; uncertainties regarding market acceptance and adoption of LightSolver's technology; the ability to develop and commercialize LightSolver's products and technology successfully; the ability to establish and expand strategic collaborations and commercial relationships; competition and technological developments; intellectual property risks; the availability of capital; CollPlant's ability to maintain compliance with Nasdaq listing requirements; general market, industry, economic and geopolitical conditions; and other risks and uncertainties described in CollPlant's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 20-F and subsequent Reports on Form 6-K. Forward-looking statements speak only as of the date of this press release. CollPlant undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Contact Information:

CollPlant
Eran Rotem
Deputy CEO & CFO
eran@collplant.com
+972.73.232.5600

LightSolver
Dr. Ruti Ben Shlomi
Co-Founder & CEO
ruti@lightsolver.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/collplant-to-host-lightsolver-investor-webinar-on-september-17-2026-302875068.html

SOURCE CollPlant

FAQ

When and how can investors join the LightSolver webinar?

The investor webinar will take place on Thursday, September 17, 2026, at 8:30 a.m. Eastern Time. Registration is available at https://www.veidan-conferencing.com/collplant.

How can attendees submit questions for the LightSolver webinar?

Attendees are invited to submit questions in advance by emailing investors@lightsolver.com by the end of the day on September 15, 2026.

What topics will LightSolver cover during the webinar?

LightSolver management will present an introduction to the company and its full-stack photonic computing architecture, explain the computational challenges and applications it targets, review current validation and collaboration programs, and outline its roadmap toward commercial deployment.

How does LightSolver change CollPlant’s business profile?

Following the acquisition of LightSolver, CollPlant operates both in regenerative medicine and in advanced high-performance computing, integrating LightSolver’s all-optical Laser Processing Unit architecture to address computationally intensive workloads in areas such as aerospace, defense, and Physical AI.